Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Charcot Marie Tooth Disease
Interventions
Placebo, Mexiletine
Other · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • Iowa City, Iowa • Kansas City, Kansas + 7 more
Conditions
Myotonic Dystrophy
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

NCT02781454
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more
Conditions
Amputation, Chronic Pain
Interventions
morphine and mexiletine
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Mexiletine hydrochloride, Benztropine mesylate, Amitriptyline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Completed Phase 4 Interventional Results available

Mexiletine for the Treatment of Muscle Cramps in ALS

NCT01811355
Conditions
Muscle Cramps in Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
Bjorn Oskarsson, MD
Other
Eligibility
21 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Chester, California • La Jolla, California • Los Angeles, California + 3 more
Conditions
Blepharospasm, Dystonia, Spasm
Interventions
Mexiletine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cryptogenic Sensory Polyneuropathy
Interventions
Nortriptyline, Duloxetine, Pregabalin, Mexiletine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Conditions
Ventricular Tachycardia
Interventions
Ventricular Tachycardia Ablation, Standard Medical Therapy, Non-Invasive Programmed Stimulation (NIPS)
Procedure · Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Myotonia, Non-Dystrophic Myotonia
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
Richard Barohn, MD
Other
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, New York + 1 more